Target family: A1: Pepsin (type: enzyme)
Target: beta-secretase 2

Ligand: example 41 [WO2012028563] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 10 pIC50
Reference (Patent): Bace inhibitors for use in the treatment of diabetes.

Ligand: example 92 [WO2012095521] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pIC50
Reference (Patent): Bace-2 inhibitors for the treatment of metabolic disorders.

Ligand: example 98 [WO2011020806] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9 pIC50
Reference (Journal): BACE2 as a new diabetes target: a patent review (2010 - 2012).
Published in: Expert Opin Ther Pat

Ligand: hydroxyethylamine transition-state inhibitor 1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.150000095367432 pIC50
Reference (Journal): Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor.
Published in: J Mol Biol

Ligand: JNJ-67569762 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.710000038146973 pIC50
Reference (Journal): JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate.
Published in: J Med Chem

Ligand: NB-360 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.300000190734863 pIC50
Reference (Journal): A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
Published in: Mol Neurodegener

Ligand: RO5508887 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.400000095367432 pIC50
Reference (Journal): Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.
Published in: J Neurosci

Ligand: umibecestat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.519999980926514 pIC50
Reference (Journal): Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious &#x3b2;-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer's Disease.
Published in: J Med Chem

Ligand: verubecestat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.920000076293945 pKi
Reference (Journal): Discovery of Extremely Selective Fused Pyridine-Derived β-Site Amyloid Precursor Protein-Cleaving Enzyme (BACE1) Inhibitors with High In Vivo Efficacy through 10s Loop Interactions.
Published in: J Med Chem

Ligand: verubecestat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.430000305175781 pKi
Reference (Patent): Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use.